A large biotech company focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics globally for patients suffering from inflammatory and auto-immune diseases, has built a clinical late stage therapeutics pipeline and is seeking collaborations with companies with compelling early-stage programs and technologies within its core therapeutic areas of interest, and is willing to consider multiple partnering structures ranging from investments (active or passive) to in-licensing. While primarily interested in therapeutics, assuming a fit with the firm’s areas of interest, the firm is willing to consider partnerships and investments around other technologies. Furthermore, the firm is willing to partner with companies across the globe.

The firm’s areas of interest are in inflammation and auto-immune conditions, with a focus on GI and dermatologic disease. Also of interest are any technologies relating to the microbiome. As a secondary interest, the firm will also consider therapeutics in the cardiovascular space.

Due to their flexibility as investors, the firm can assume varying roles in a partnership depending on the level of investment. When investing alongside other firms, the firm will not necessarily require exclusive rights to the assets. For larger investments, where the firm is supporting the majority of development activities, they generally will assume an involved role as a more pro-active partner with the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life sciences investment fund dedicated to accelerating the growth of seed-stage therapeutics companies with a partnership with a USA-based family investment office, seeks to make 3-5 new investments per year allocating up to $250,000 per company. The firm invests in companies based in the U.S.

The firm is seeking investments in biotech/therapeutics companies and is not interested in medical device or digital health technologies. The firm is interested in companies with assets or platform technologies in preclinical or early clinical development and is indication agnostic.

The firm does not have any company management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Western Europe with multiple funds raised to date, generally makes equity investments into internet and health tech companies at seed and early stages. The typical investment size ranges from €0.2 million to € 2 million. The firm plans to make 15-20 investments in the next 3 years and the firm will invest in companies based in Europe with a focus on Switzerland and Germany.

The firm is currently looking for new opportunities in the area of platform technologies, diagnostics, digital health, etc. The firm focuses on companies developing biotech platforms, research tools and nutrition in preclinical and clinical stages. The firm will not invest in drug development companies or medical device companies. In the past, the firm was active in companies developing proteomics platform technology, 3D micro tissues technology, diagnostic services, vaccines, and technology platform to develop virus envelopes.

The firm typically seeks to invest in private companies with convincing founders or managers. The firm will consider pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A new venture capital firm founded in 2018 and based in China is focused on big data and IOT-related healthcare investment opportunities. The firm is currently managing a 500 million RMB fund and is actively looking to invest 10-20 new deals in the following 12 months. The firm invests mostly in Medical Devices, Diagnostics, and Digital Health companies but will also consider drugs in applicable cases. The firm is currently looking for new opportunities globally, however, following China’s latest healthcare development strategy would be an important consideration although not required for their investment opportunities. The size of investment can vary from 10 – 30 million RMB depending on the deal.

The firm is interested in medtech, diagnostics, and digital health companies that are seeking for early financing round. The firm’s sweet spot is to invest in angel to pre-A round. The firm will not invest in B round or later rounds. The firm is especially interested in technology with a big-data component. The firm has invested in molecular diagnostics and digital health companies. The firm is opportunistic in terms of subsectors and indications.

The firm is seeking to invest in management teams with strong research or industry background. Management teams that graduated from the world’s top universities or has worked for big pharma is a plus. The firm also prefers serial entrepreneurs with successful track records.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Western Europe invests focuses on investments in technology-based early stage companies in life science industry among other technologically oriented industries. The venture capitalist provides initial investments of up to €600,000-1 million. The firm will also reserve a further €3 million for follow-on financing and supports the start-ups in acquiring other investors and partners. The firm is interested in companies that have been in operation for less than one year. The firm typically looks to make 10-15 life science investments per year. The firm invests primarily in Germany but also has the capacity to invest in other parts of Europe or in global companies that have ties to Germany. The firm only invests in companies that are less than 3 years old.

The firm is looking for new opportunities in the life science space including therapeutics, diagnostics, medical devices, material sciences, chemicals, regenerative energies and healthcare IT sectors. The firm is opportunistic in terms of sector, subsectors and indications, but it focuses on companies with a significant technological innovation and close to proof of concept. The firm’s investments to date have included life science companies developing medical devices, vaccines, drugs development, diagnostic services, chemicals and platform technologies.

The firm mostly invests in seed-stage companies located in Germany (or at least have a German subsidiary) with deep technological knowledge and expertise. The target market should be large and/or have high growth potential. The founding team should have the relevant know-how, complimentary skills and relevant business / industry experience. Outside of Germany, the firm only invests as a co-investor alongside a local lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with multiple offices throughout Western Europe has raised 6 funds to date, and allocates up to €10M in equity per company. The firm’s investment focus is on fast growing high-tech companies in global technology markets such as telecommunications and IT, internet/media, nanotechnology, new materials, electronics, cleantech and life science. The firm invests in companies that are based in Europe. The firm is actively seeking new investments.

In the Life Sciences, the firm seeks to invest in early-stage therapeutic discovery/technology platform, R&D services, and medical device companies. For medical devices, the firm prefers products that are close to market commercialization. The firm is opportunistic in terms of subsectors and indications. Historically, the firm invested in proteomics, CRO, cell-based expression systems, small molecule drug discovery, cell modeling/viral vector platforms, cancer diagnostics, and drug delivery. The firm does not invest in drug development.

The firm requests a board seat in each portfolio company. The firm seeks a company with a strong management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A privately-owned designer, developer and manufacturer of advanced drug delivery systems who is active in R&D, design and manufacturing in all areas of healthcare, is actively seeking partnering opportunities with early-stage companies. The firm is capable of a variety of deal structures, but prefers to enter into joint ventures and strategic partnerships as the firm seeks to be a value-added investor providing their expertise and capabilities in design and manufacturing as well as the resources of a large company while allowing the entrepreneur to drive the development of the technology.

The firm’s expertise lies in drug delivery devices, but has capabilities and is highly interested in all areas of medical technology/devices, biosensors and wearables, B2B or B2C healthcare IT applications including data analytics and cloud computing as well as robotics and AI as it applies to surgery prosthetics, rehabilitation and drug discovery. The firm has a particular interest in the diabetes space and has done work in this area in the past.

The firm is open to working with all entrepreneurs and is open to companies on a global basis. The firm does look for a board seat along with an investment, but strives to not be restrictive in any way and let the management team run the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.